Skip to Main content Skip to Navigation
Book sections

Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma

Abstract : Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ) significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell lymphoma (MCL), two of the most challenging B cell malignancies in western countries. However, relapses following BTZ therapy are frequent, while primary resistance to this agent remains a major limitation for further development of its therapeutic potential. In the present chapter, we recapitulate the molecular mechanisms associated with intrinsic and acquired resistance to BTZ learning from MM and MCL experience, including mutations of crucial genes and activation of prosurvival signalling pathways inherent to malignant B cells. We also outline the preclinical and clinical evaluations of some potential druggable targets associated to BTZ resistance, considering the most meaningful findings of the past 10 years. Although our understanding of BTZ resistance is far from being completed, recent discoveries are contributing to develop new approaches to treat relapsed MM and MCL patients.
Complete list of metadata
Contributor : Brigitte Sola Connect in order to contact the contributor
Submitted on : Monday, October 19, 2020 - 3:18:19 PM
Last modification on : Thursday, September 1, 2022 - 11:13:46 AM

Links full text



Maria Gonzalez-Santamarta, Grégoire Quinet, Diana Reyes-Garau, Brigitte Sola, Gaël Roué, et al.. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma. Proteostasis and Disease, Springer, pp.153-174, 2020, Advances in experimental medicine and biology, ⟨10.1007/978-3-030-38266-7_6⟩. ⟨hal-02971497⟩



Record views